Immunotherapy has transformed cancer care, offering a way to harness the body’s own immune system to fight tumors. But even with these advances, many patients still don’t respond. One major barrier to ...
BRB-002 is an immunomodulatory agent that inhibits the CD47 cell surface receptor (“don’t eat me” signal) to ameliorate the underlying causes of atherosclerosis and reduce inflammatory plaque burden.
Risk of myelodysplastic syndrome and myeloproliferative neoplasms in patients with stable coronary artery disease and autoimmune conditions treated with colchicine. This is an ASCO Meeting Abstract ...
Researchers from the USC Norris Comprehensive Cancer Center and collaborators report that they have found evidence that targeting CD47, a protein that is part of the innate immune system, could be a ...
CD47-null femoral fractures show reduced bone formation, but increased tissue mineral density. µCT analysis of transverse femoral fracture in WT (n = 9) and CD47-null (n = 11-14) mice at 10- and ...
A new research paper was published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results